Pfizer and BioNTech ask FDA to authorize their COVID-19 vaccine in children; the World Health Organization (WHO) recommended widespread use of the world’s first malaria vaccine; a US judge blocks Texas’ strict abortion law.
Pfizer and BioNTech said Thursday they are asking the FDA to approve their COVID-19 vaccine for children aged 5-11, The New York Times reported. An emergency use authorization (EUA) is expected between Halloween and Thanksgiving. The companies are proposing to give pediatric patients one-third of the adult dose. The delta variant was responsible for hospitalizing 30,000 children in August alone.
The World Health Organization (WHO) announced that it is greenlighting the world’s first and only vaccine against malaria among children in sub-Saharan Africa and other regions where there is a moderate to high risk of contracting malaria, according to a report from CNN. The recommendation is based on preliminary results from an ongoing pilot program on vaccinations in child health clinics across Ghana, Kenya, and Malawi. The vaccine was found to be safe, cost-effective, feasible to deliver and significantly reduced deadly severe malaria by about 30%, according to the WHO.
A federal judge issued a temporary block on Texas’ strict abortion law, which bans abortions for pregnant people after 6 weeks, in response to the Biden administration challenging the law, Reuters reported. The block comes after the Supreme Court voted in a 5-4 decision to allow the law to go into effect last month. Shortly after, Texas notified the court that it intends to appeal the ruling to the Fifth Circuit Court of Appeals, which is currently conservative leaning. The block sets up the next phase of the legal battle on abortion rights, especially as other states are attempting to implement similar laws.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Long COVID Disparities Revealed in New Study From England
March 18th 2025A new analysis out of England shows a considerable level of uncertainty among adults who think they could have long COVID, as well that levels of the chronic condition are disproportionately higher among certain socially disadvantaged groups.
Read More